ABIVAX Société Anonyme ABVX

Full chart Compare
Set alert

Price alert · ABVX

All alert types
90.02 USD +1.31 (+1.48%)

Nov 4, 2026, 9:31 AM EST

90.39 Day range 90.60
69.81 52-week range 148.83
YTD
-33.24%
1 year
-8.93%

Discussion (3)

Sign in to join the discussion

Tim F ABVX 5 months ago #1

What a shit show that was. Beat the living hell outta it and then buy it back hand over fist…what?

Tim F ABVX 9 months ago #2

Somebody wants this pharma company

Member ABVX 10 months ago #3

Abvx/Abivax: "Strong Buy" On Obefazimod New UC Data And Maintenance Results Coming Q2 2026
Terry Chrisomalis
Summary

Abivax SA (ABVX) retains a "Strong Buy" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ulcerative colitis.
Upcoming catalysts include 44-week maintenance data from ABTECT trials in Q2 2026 and potential NDA/MAA filings in H2 2026, contingent on positive results.
Obefazimod's oral dosing, favorable safety, and novel miR-124 mechanism position ABVX to penetrate 2nd/3rd-line UC therapy, move to 1st-line and expand into Crohn's disease.
Recent $700M+ capital raise extends cash runway into Q4 2027, supporting ongoing pivotal trials and strategic expansion opportunitie